IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of claims:

Claim 1 (**currently amended**): A compound of formula **(I)**:



(I)

wherein:

~~**p is 0;**~~

R^2 is amino, R^6 or R^6-NH-;

R^3 is hydrogen, halo or cyano;

R^4 is C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-4}alkyl, or heterocyclyl;

R^5 is C_{1-6}alkyl or C_{2-6}alkenyl; wherein R^5 may be optionally substituted on carbon by one or more methoxy;

R^6 is C_{1-4}alkyl, C_{2-4}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl, or (heterocyclic group)C_{1-3}alkyl; wherein R^6 may be optionally substituted on carbon by one or more methoxy, ethoxy or trifluoromethyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 2 (**cancelled**).

Claim 3 (**previously presented**): The compound of formula **(I)** according to claim 1 wherein R^2 is R^6-NH- wherein R^6 is C_{1-4}alkyl, C_{2-4}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl or (heterocyclic group)C_{1-3}alkyl; and wherein R^6 may be optionally substituted on carbon by one methoxy, ethoxy or trifluoromethyl; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 4 (**previously presented**): The compound of formula **(I)** according to claim 1 wherein R^3 is hydrogen; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claims 5-6 (**cancelled**).

Claim 7 (**currently amended**): The compound of formula **(I)** as claimed in claim 1 wherein:

~~p is 0;~~

R^2 is methylamino, allylamino, *t*-butylamino, 2-methoxyethylamino, 2-ethoxyethylamino, 3-methoxypropylamino, cyclopropylamino, cyclobutylamino, cyclopropylmethylamino, 2,2,2-trifluoroethylamino, tetrahydrofur-2-ylmethylamino or pyrid-2-ylmethylamino;

R^3 is hydrogen;

R^4 is cyclopropylmethyl, 2-cyclopropylethyl, cyclobutyl, cyclopropyl, cyclopentyl or tetrahydrofur-3-yl;

R^5 is methyl, ethyl, propyl, methoxymethyl or 2-methylprop-1-enyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 8 (**previously presented**): The compound of formula **(I)** as claimed in claim 1 selected from:

4-(1-cyclopentyl-2-methylimidazol-5-yl)-2-{4-[*N*-(cyclopropyl)sulphamoyl]anilino} pyrimidine;

4-(1-cyclopropylmethyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl] anilino}pyrimidine;

4-(1-cyclopropylmethyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2,2,2-trifluoroethyl)sulphamoyl] anilino}pyrimidine;

4-(1-cyclopropylmethyl-2-methylimidazol-5-yl)-2-{4-[*N*-(cyclobutyl)sulphamoyl] anilino}pyrimidine;

4-(1-cyclopropylethyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl] anilino}pyrimidine;

4-(1-cyclopropylethyl-2-methylimidazol-5-yl)-2-{4-[*N*-(tetrahydrofur-2-ylmethyl) sulphamoyl]anilino}pyrimidine;

4-(1-cyclopropylethyl-2-methoxymethylimidazol-5-yl)-2-{4-[*N*-(2-ethoxyethyl)sulphamoyl] anilino}pyrimidine; and

4-(1-cyclopropylmethyl-2-ethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl) sulphamoyl]anilino}pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 9 (**currently amended**): A process for preparing a compound of formula **(I)** as claimed in claim 1 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof which process (wherein ~~R^1~~, R^2, R^3, R^4, R^5 and p are, unless otherwise specified, as defined in claim 1) comprises of:

Process a) reaction of a pyrimidine of formula **(II)**:



(II)

wherein L is a displaceable group; with an aniline of formula **(III)**:



(III)

or

Process b) reacting a compound of formula **(IV)**:



(IV)

with a compound of formula **(V)**:



(V)

wherein T is O or S; R^x may be the same or different and is C_{1-6}alkyl;

Process c) for compounds of formula **(I)** where R^2 is amino or a group R^6-NH-; reacting a pyrimidine of formula **(VI)**:



(VI)

wherein X is a displaceable group; with an amine of formula **(VII)**:

$$R^a\text{-}NH_2$$

(VII)

wherein R^a is hydrogen or R^6;

Process d) reacting a pyrimidine of formula **(VIII)**



(VIII)

with a compound of formula **(IX)**:



(IX)

where Y is a displaceable group; or

Process e) for compounds of formula **(I)** wherein R^2 is R^6; oxidising a compound of formula **(X)**:



(X)

and thereafter optionally:

i) converting a compound of the formula **(I)** into another compound of the formula **(I)**;

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

Claim 10 (**currently amended**): A pharmaceutical composition which comprises a compound of the formula **(I)**, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1, ~~2-4~~ 3-4 and 7-8, in association with a pharmaceutically-acceptable diluent or carrier.

Claims 11-13 (**cancelled**).

Claim 14 (**currently amended**): A method for the treatment of ~~solid tumour cancers and leukaemias, fibroproliferative and differentiative disorders, psoriasis,~~ rheumatoid arthritis, ~~Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation,~~ which method comprises administering to said animal an effective amount of a compound of the formula **(I)**, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1, 3-4 and 7-8.

Claims 15-20 (**cancelled**).